Bli medlem
Bli medlem

Du är här


Nexstim Oyj: Nexstim Plc Appoints John Liedtky as VP of Commercialization, General Manager US and announces the retirement of John Hardin

Company Announcement, Helsinki, 1 April 2016 at 9:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients with the use of non-invasive brain
stimulation, today announces the appointment of John Liedtky as VP of
Commercialization, General Manager US, effective from 1 April 2016. Mr.
Liedtky will also join Nexstim Management Team and will be responsible of
Pre-Surgical Mapping business and commercial development of therapeutic
indications. At the same time, Nexstim announces the planned retirement of
John Hardin, Vice President, Pre-surgical Mapping from Nexstim's Management
Team on 6 May 2016.

John Liedtky is a global healthcare executive with extensive experience in the
medical device and equipment space, having previously held Global Marketing
Vice Presidency Roles at DJO Global, COVIDIEN and BREG Inc. John Liedtky is
an expert in leading cross-functional teams through the complete product
life-cycle, from upstream development to strategic downstream marketing and
sales management tactics, and has experience with a breadth of technologies
and business models in both the US and Internationally.

Nexstim's CEO, Janne
Huhtala, said:
welcome John Liedtky to the team as we continue to grow in the important US
market, both in PSM and therapeutic indications. We thank John Hardin for
the significant contribution that he has made to Nexstim and are grateful for
all that he has done for pre-surgical mapping, our NBS system and the
Company. We wholeheartedly wish him well for the future.

Janne Huhtala, CEO

For further information please visit
www.nexstim.comor contact:


+358 (0)40 8615046
Janne Huhtala, Chief Executive Officer

UB Securities Ltd
(Certified Adviser)
+358 (0)9 2538 0246

Consilium Strategic Communications
+44 (0)20
3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for
stroke patients. Nexstim has pioneered its technology in brain diagnostics
with the Navigated Brain Stimulation (NBS) system as the first and only
FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS)
device for pre-surgical mapping of the motor and speech cortices. Based on
the same technology platform, the company has developed a device for stroke
therapy called Navigated Brain Therapy (NBT®). Nexstim's shares are listed on
Nasdaq First North Finland and Nasdaq First North Sweden. For more
information please

Nexstim Plc


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.